Novel 3D printing concept for the fabrication of time-controlled drug delivery systems
Novel 3D printing concept for the fabrication of time-controlled drug delivery systems
复制标题
DOI：
10.1515/cdbme-2018-0035
复制
发表时间：
2018-09
影响因子：
--
通讯作者：
J. Konasch;Alexander Riess;M. Teske;Natalia Rekowska;R. Mau;T. Eickner;N. Grabow;H. Seitz
中科院分区：
文献类型：
--
作者：
J. Konasch;Alexander Riess;M. Teske;Natalia Rekowska;R. Mau;T. Eickner;N. Grabow;H. Seitz
摘要三维（3D）打印已成为许多领域的流行技术。一个新兴领域是使用3D打印来开发3D药物输送系统（DDS）和载药医疗器械。本文介绍了一种新的概念，用于制造的时间控制的药物输送系统的基础上立体光刻结合喷墨打印。喷墨打印头和UV-LED光源已经集成到现有的立体光刻系统中。喷墨打印用于在立体光刻3D打印过程中选择性地掺入活性药物成分（API）。在最初的实验研究中，聚（乙二醇）二丙烯酸酯（PEGDA）用作聚合物，而2-羟基-4 '-（2-羟基乙氧基）-2-甲基苯丙酮（Irgacure 2959）和苯基-2，4，6-三甲基苯甲酰基次膦酸锂（Lithium phenyl-2，4，6-trimethylbenzoylphosphinate，简称PPhP）用作光引发剂。基本结构可以通过新的混合3D打印系统成功制造。
Abstract Three-dimensional (3D) printing has become a popular technique in many areas. One emerging field is the use of 3D printing for the development of 3D drug delivery systems (DDS) and drug-loaded medical devices. This article describes a novel concept for the fabrication of timecontrolled drug delivery systems based on stereolithography combined with inkjet printing. An inkjet printhead and an UV-LED light source have been integrated into an existing stereolithography system. Inkjet printing is used to selectively incorporate active pharmaceutical ingredients (API) during a stereolithographic 3D printing process. In an initial experimental study, poly (ethylene glycol) diacrylate (PEGDA) was used as polymer whereas 2-Hydroxy-4´-(2- hydroxyethoxy)-2-methylpropiophenone (Irgacure 2959) and Lithium phenyl-2,4,6-trimethylbenzoylphosphinate (LAP) were used as photoinitiators. Basic structures could be manufactured successfully by the new hybrid 3D printing system.